Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, at a public offering price of $32.50 per share. Ra Pharma also granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $130 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Ra Pharma.